

20 December 2024

GSK HQ
78 New Oxford St.
London
WC1A 1DG
T +44 (0) 8047 5000

Dear Healthcare Professional,

Notification of Seroxat® (paroxetine hydrochloride) 10mg, 20mg and 30mg tablets discontinuation

GlaxoSmithKline UK Limited, in agreement with the Medicines and Healthcare products Regulatory Agency (MHRA) would like to inform you of the following:

Key Message

The purpose of this letter is to inform Health Care Providers about the discontinuation of Seroxat® (paroxetine hydrochloride) 10mg, 20mg and 30mg tablets.

Action Being Taken by GlaxoSmithKline

- GSK has notified the MHRA and DHSC that Seroxat® 20mg tablets will be discontinued in the UK from March 2025, Seroxat® 30mg from May 2025 and Seroxat® 10mg from November 2025 for commercial reasons.
- Limited stock of Seroxat® may remain available in the market for some weeks after until this stock is exhausted. Pharmacies will be able to order these through their normal wholesale routes.

Action required by Health Care Providers

Healthcare Providers are advised that:

Paroxetine is a selective serotonin re-uptake inhibitor (SSRI) antidepressant. Seroxat® tablets (10, 20, 30 mg) are indicated for the treatment of: Major Depressive Episode; Obsessive Compulsive Disorder; Panic Disorder with and without agoraphobia; Social Anxiety Disorders/Social phobia; Generalised Anxiety Disorder; Post-Traumatic Stress Disorder

- Generic versions of Paroxetine hydrochloride 10mg, 20mg and 30mg tablets are available.
- In general, switching or stopping medicines can carry medical risk and should be supervised by a physician.
- For paroxetine (in common with other SSRIs), abrupt discontinuation should be avoided as this may result in withdrawal symptoms (refer to the Summary of Product Characteristics for details).
- The choice of SSRI should depend on the clinical assessment of each patient.

You should share this information with relevant health care personnel under your supervision.

Call for reporting

Please continue to report suspected adverse drug reactions (ADRs) to the MHRA through the Yellow Card scheme.

Please report:

- all suspected ADRs that are serious or result in harm. Serious reactions are those that are fatal, life-threatening, disabling or incapacitating, those that cause a congenital abnormality or result in hospitalisation, and those that are considered medically significant for any other reason
- all suspected ADRs associated with new drugs and vaccines identified by the black triangle ▼

You can report via:

- the [Yellow Card website](#)
- the free Yellow Card app available from the Apple App Store or Google Play Store
- some clinical IT systems (EMIS/SystemOne/Vision/MiDatabank) for healthcare professionals

Alternatively, you can report a suspected side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm.

When reporting please provide as much information as possible, including information about medical history, any concomitant medication, timing onset, treatment dates, and product brand name.

Company contacts point

If you have any questions about this letter or require more information about Seroxat®, please call 0800 221 441 (option 2), 8:30am to 5:00pm GMT, Monday to Friday, or email ukmedinfo@gsk.com

Yours faithfully,



*Electronically signed by: Dr Hubert
Bland MBChB FFPM
Reason: I am signing for the
reasons as stated in the document.
Date: Dec 16, 2024 16:14 GMT*

Dr Hubert Bland
Country Medical Director, UK and Ireland